Mouwasat Medical Services Company
TADAWUL:4002.SR
94.5 (SAR) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SAR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,705.51 | 2,334.112 | 2,144.143 | 2,045.032 | 1,857.208 | 1,677.019 | 1,507.138 | 1,244.781 | 1,000.083 | 969.888 | 902.236 | 618.516 | 678.441 | 587.49 | 517.595 | 454.553 | 400.67 |
| Cost of Revenue
| 1,392.43 | 1,235.174 | 1,148.365 | 1,084.735 | 1,027.937 | 903.52 | 794.971 | 669.796 | 553.277 | 486.612 | 446.437 | 796.514 | 354.444 | 310.437 | 289.591 | 253.652 | 227.277 |
| Gross Profit
| 1,313.08 | 1,098.938 | 995.778 | 960.297 | 829.27 | 773.499 | 712.167 | 574.985 | 446.805 | 483.276 | 455.798 | -177.998 | 323.997 | 277.053 | 228.004 | 200.901 | 173.393 |
| Gross Profit Ratio
| 0.485 | 0.471 | 0.464 | 0.47 | 0.447 | 0.461 | 0.473 | 0.462 | 0.447 | 0.498 | 0.505 | -0.288 | 0.478 | 0.472 | 0.441 | 0.442 | 0.433 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 88.14 | 71.107 | 51.655 | 48.905 | 52.376 | 44.827 | 43.578 | 25.669 | 22.209 | 21.61 | 20.448 | 87.213 | 79.221 | 79.675 | 68.753 | 63.545 | 77.209 |
| Selling & Marketing Expenses
| 35.174 | 28.263 | 26.819 | 28.148 | 33.305 | 16.734 | 14.096 | 16.565 | 7.745 | 3.129 | 6.955 | 98.924 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 123.314 | 99.37 | 78.474 | 77.052 | 85.681 | 61.561 | 57.674 | 42.234 | 29.953 | 24.739 | 27.403 | 186.137 | 79.221 | 79.675 | 68.753 | 63.545 | 77.209 |
| Other Expenses
| -556.22 | 336.477 | 295.375 | 305.409 | 273.102 | 7.183 | 8.385 | 10.796 | 8.076 | 7.862 | 8.101 | 0.529 | 0 | 3.658 | 2.705 | -31.103 | -8.395 |
| Operating Expenses
| 556.22 | 435.847 | 373.849 | 382.462 | 358.783 | 369.438 | 340.641 | 288.231 | 211.902 | 250.11 | 233.55 | 186.666 | 79.221 | 83.333 | 71.458 | 68.288 | 72.18 |
| Operating Income
| 756.86 | 663.091 | 621.929 | 577.835 | 470.487 | 404.061 | 371.526 | 286.754 | 234.903 | 233.166 | 222.248 | -364.664 | -403.218 | -360.386 | -299.461 | -269.189 | -245.573 |
| Operating Income Ratio
| 0.28 | 0.284 | 0.29 | 0.283 | 0.253 | 0.241 | 0.247 | 0.23 | 0.235 | 0.24 | 0.246 | -0.59 | -0.594 | -0.613 | -0.579 | -0.592 | -0.613 |
| Total Other Income Expenses Net
| -756.86 | -2.82 | 10.267 | -0.968 | -8.257 | 4.631 | 8.021 | 8.918 | 4.299 | 34.306 | 10.14 | 544.809 | -80.718 | -66.685 | -44.657 | -31.103 | -8.395 |
| Income Before Tax
| 727.088 | 660.271 | 632.196 | 576.868 | 462.23 | 408.691 | 379.547 | 295.672 | 239.202 | 267.472 | 232.389 | 180.145 | 164.058 | 127.035 | 111.889 | 101.51 | 92.818 |
| Income Before Tax Ratio
| 0.269 | 0.283 | 0.295 | 0.282 | 0.249 | 0.244 | 0.252 | 0.238 | 0.239 | 0.276 | 0.258 | 0.291 | 0.242 | 0.216 | 0.216 | 0.223 | 0.232 |
| Income Tax Expense
| 38.699 | 27.584 | 21.735 | 15.242 | 13.466 | 24.39 | 23.326 | 21.823 | 16.084 | 16.798 | 13.666 | 8.551 | 16.004 | 8.47 | 4.845 | 4.438 | 4.059 |
| Net Income
| 657.688 | 599.305 | 578.161 | 528.157 | 421.029 | 360.207 | 336.733 | 255.883 | 208.802 | 240.118 | 201.2 | 158.16 | 148.054 | 118.566 | 107.044 | 97.072 | 88.759 |
| Net Income Ratio
| 0.243 | 0.257 | 0.27 | 0.258 | 0.227 | 0.215 | 0.223 | 0.206 | 0.209 | 0.248 | 0.223 | 0.256 | 0.218 | 0.202 | 0.207 | 0.214 | 0.222 |
| EPS
| 3.29 | 3 | 2.89 | 2.64 | 2.11 | 1.8 | 1.69 | 1.29 | 1.05 | 1.2 | 1 | 0.86 | 0.74 | 0.59 | 0.54 | 0.49 | 0.44 |
| EPS Diluted
| 3.29 | 3 | 2.89 | 2.64 | 2.11 | 1.8 | 1.69 | 1.29 | 1.05 | 1.2 | 1 | 0.86 | 0.74 | 0.59 | 0.54 | 0.49 | 0.44 |
| EBITDA
| 1,113.98 | 871.459 | 797.906 | 738.857 | 626.919 | 524.497 | 475.59 | 376.683 | 300.631 | 286.472 | 274.285 | -325.47 | 245.557 | 194.839 | 187.872 | 159.427 | 127.24 |
| EBITDA Ratio
| 0.412 | 0.373 | 0.372 | 0.361 | 0.338 | 0.313 | 0.316 | 0.303 | 0.301 | 0.295 | 0.304 | -0.526 | 0.362 | 0.332 | 0.363 | 0.351 | 0.318 |